{
  "main_header": {
    "sid": 10039665,
    "name": "Anthem Bioscienc",
    "stock_name": "Anthem Bioscienc",
    "full_name": "Anthem Biosciences Ltd",
    "name_url": "stocks-analysis/anthem-bioscienc",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "662.00",
    "chg": -5.05,
    "chgp": "-0.76%",
    "dir": -1,
    "prev_price": "667.05",
    "mcapval": "36,834.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 544449,
    "symbol": "ANTHEM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0CZ201020",
    "curr_date": "Apr 02",
    "curr_time": "",
    "bse_nse_vol": "3.59 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 02, 2026",
    "traded_date_str": "2026 04 02",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/anthem-bioscienc-10039665-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [],
    "total": 4,
    "sid": "10039665",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/anthem-biosciences-10039665"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Mar-2026",
      "details": "Closure of Trading Window for the quarter and year ended March 31 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Cessation",
      "datetime": "13-Mar-2026",
      "details": "Anthem Biosciences Limited hereby informs the exchange of the resignation of Mr. K Ramakrishnan from the position of General Counsel and consequently from the role of Senior Management Personnel of the Company with effect from March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations)",
      "datetime": "23-Feb-2026",
      "details": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2025 we hereby inform that the Company has executed on February 23 2026 First amendment to the Loan agreement dated April 15 2024 entered with Neoanthem Lifesciences Private Limited (Wholly Owned Subsidiary).",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

No Recent News for the Company

View All News